JPWO2019180631A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019180631A5 JPWO2019180631A5 JP2020549740A JP2020549740A JPWO2019180631A5 JP WO2019180631 A5 JPWO2019180631 A5 JP WO2019180631A5 JP 2020549740 A JP2020549740 A JP 2020549740A JP 2020549740 A JP2020549740 A JP 2020549740A JP WO2019180631 A5 JPWO2019180631 A5 JP WO2019180631A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lymphoma
- compound according
- alkyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 208000019838 Blood disease Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 230000002611 ovarian Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000002307 prostate Anatomy 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000028782 Hereditary disease Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 208000012868 Overgrowth Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000003849 large cell carcinoma Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- -1 -NR eR f Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023052481A JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841010656 | 2018-03-22 | ||
| IN201841010656 | 2018-03-22 | ||
| PCT/IB2019/052252 WO2019180631A1 (en) | 2018-03-22 | 2019-03-20 | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Division JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518366A JP2021518366A (ja) | 2021-08-02 |
| JPWO2019180631A5 true JPWO2019180631A5 (https=) | 2022-03-29 |
| JP2021518366A5 JP2021518366A5 (https=) | 2022-03-29 |
| JP7254094B2 JP7254094B2 (ja) | 2023-04-07 |
Family
ID=67986029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549740A Active JP7254094B2 (ja) | 2018-03-22 | 2019-03-20 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11542275B2 (https=) |
| EP (1) | EP3768671B1 (https=) |
| JP (2) | JP7254094B2 (https=) |
| KR (1) | KR102767362B1 (https=) |
| CN (1) | CN112105609A (https=) |
| AU (1) | AU2019237329B2 (https=) |
| BR (1) | BR112020019111A2 (https=) |
| CA (1) | CA3092770A1 (https=) |
| CU (1) | CU24627B1 (https=) |
| EA (1) | EA202092253A1 (https=) |
| ES (1) | ES2982859T3 (https=) |
| IL (1) | IL277518B2 (https=) |
| MX (1) | MX2020009738A (https=) |
| MY (1) | MY203159A (https=) |
| PH (1) | PH12020551494A1 (https=) |
| SG (1) | SG11202008526VA (https=) |
| WO (1) | WO2019180631A1 (https=) |
| ZA (1) | ZA202006137B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768670A4 (en) * | 2018-03-22 | 2021-11-24 | Aurigene Discovery Technologies Limited | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| CN115232147B (zh) * | 2022-08-09 | 2023-10-13 | 南方科技大学 | 一种作为HIF-2α激动剂的杂环衍生物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69729583T2 (de) * | 1996-04-17 | 2005-06-09 | Bristol-Myers Squibb Pharma Co. | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren |
| UY32730A (es) * | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| AU2012249421B9 (en) * | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
| IN2012CH00067A (https=) * | 2012-01-06 | 2017-08-04 | ||
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9611257B2 (en) * | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| JP6510485B2 (ja) | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| GB201604027D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| EP3266784A1 (en) | 2016-06-08 | 2018-01-10 | Pierre Fabre Medicament | Protein arginine n-methyltransferases inhibitors and uses thereof |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
-
2019
- 2019-03-20 EP EP19771397.7A patent/EP3768671B1/en active Active
- 2019-03-20 SG SG11202008526VA patent/SG11202008526VA/en unknown
- 2019-03-20 CN CN201980029962.0A patent/CN112105609A/zh active Pending
- 2019-03-20 CA CA3092770A patent/CA3092770A1/en active Pending
- 2019-03-20 WO PCT/IB2019/052252 patent/WO2019180631A1/en not_active Ceased
- 2019-03-20 BR BR112020019111-6A patent/BR112020019111A2/pt unknown
- 2019-03-20 US US16/982,800 patent/US11542275B2/en active Active
- 2019-03-20 EA EA202092253A patent/EA202092253A1/ru unknown
- 2019-03-20 AU AU2019237329A patent/AU2019237329B2/en active Active
- 2019-03-20 MY MYPI2020004843A patent/MY203159A/en unknown
- 2019-03-20 IL IL277518A patent/IL277518B2/en unknown
- 2019-03-20 JP JP2020549740A patent/JP7254094B2/ja active Active
- 2019-03-20 CU CU2020000067A patent/CU24627B1/es unknown
- 2019-03-20 MX MX2020009738A patent/MX2020009738A/es unknown
- 2019-03-20 KR KR1020207030078A patent/KR102767362B1/ko active Active
- 2019-03-20 ES ES19771397T patent/ES2982859T3/es active Active
-
2020
- 2020-09-17 PH PH12020551494A patent/PH12020551494A1/en unknown
- 2020-10-02 ZA ZA2020/06137A patent/ZA202006137B/en unknown
-
2023
- 2023-03-28 JP JP2023052481A patent/JP2023082088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019180631A5 (https=) | ||
| JP2021518366A5 (https=) | ||
| EP3915989B1 (en) | Jak inhibitor and preparation method therefor | |
| AU2018360847B2 (en) | Modulators of the integrated stress pathway | |
| JP2025023997A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| AU2017260363B2 (en) | Modulators of the integrated stress pathway | |
| KR102810546B1 (ko) | 암의 치료를 위한 4'-티오-뉴클레오타이드 및 -뉴클레오사이드 전구약물 | |
| WO2019223766A1 (zh) | 一种fgfr抑制剂、其制备方法和在药学上的应用 | |
| EP3632906B1 (en) | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | |
| PH12015501653B1 (en) | Serine/threonine kinase inhibitors | |
| Almashal et al. | A click synthesis, molecular docking, cytotoxicity on breast cancer (MDA-MB 231) and anti-HIV activities of new 1, 4-disubstituted-1, 2, 3-triazole thymine derivatives | |
| JP2012153722A5 (https=) | ||
| EP3083623A1 (en) | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one | |
| TW201906838A (zh) | Ｅｐ３００／ｃｒｅｂｂｐ抑制劑 | |
| JP2020503376A5 (https=) | ||
| RU2017139771A (ru) | Бициклические соединения | |
| KR101739083B1 (ko) | 세포 증식성 질환 치료용 플래티넘 화합물, 그 제조방법 및 용도 | |
| EP3119199A1 (en) | Compounds and their methods of use | |
| CN104829613B (zh) | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 | |
| CN111454254B (zh) | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 | |
| JP7293404B2 (ja) | ｃ－ＭＥＴ／ＡＸＬ阻害剤の結晶形 | |
| EP4261211A1 (en) | Dihydroisoquinolinone derivative and application thereof | |
| Chung et al. | Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors | |
| WO2019080724A1 (zh) | 核苷磷酸类化合物及其制备方法和用途 | |
| CA2887025C (en) | 2,3'-anhydro-2'-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application |